{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T22:02:50Z","timestamp":1768773770202,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.yebeh.2020.107580","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T22:02:11Z","timestamp":1606168931000},"page":"107580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy"],"prefix":"10.1016","volume":"113","author":[{"given":"Kuan-Ying","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-Pei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2020.107580_b0005","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(18)30454-X","article-title":"Global, regional, and national burden of epilepsy, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Beghi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2020.107580_b0010","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1474-4422(04)00906-8","article-title":"Chronic epilepsy and cognition","volume":"3","author":"Elger","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2020.107580_b0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11065-007-9043-9","article-title":"Neuropsychological and behavioral effects of antiepilepsy drugs","volume":"17","author":"Loring","year":"2007","journal-title":"Neuropsychol Rev"},{"key":"10.1016\/j.yebeh.2020.107580_b0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1528-1157.42.s8.8.x","article-title":"Cognitive and behavioral effects of epilepsy treatment","volume":"42","author":"Loring","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107580_b0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.yebeh.2013.07.013","article-title":"Which drug-induced side effects would be tolerated in the prospect of seizure control?","volume":"29","author":"Witt","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107580_b0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.seizure.2013.11.009","article-title":"Side-effects of antiepileptic drugs: the economic burden","volume":"23","author":"de Kinderen","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107580_b0035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1756285611417920","article-title":"The cognitive impact of antiepileptic drugs","volume":"4","author":"Eddy","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2020.107580_b0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","article-title":"Current understanding of the mechanism of action of the antiepileptic drug lacosamide","volume":"110","author":"Rogawski","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.107580_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008841.pub2","article-title":"Lacosamide add-on therapy for partial epilepsy","author":"Weston","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2020.107580_b0050","unstructured":"Shishmanova-Doseva M, Peychev L, Georgieva K. Effect of lacosamide and lamotrigine on cognitive functions in pentylentetrazole kindled rats. Comptes rendus de l\u2019Acad\u00e9mie bulgare des Sciences 2015;68."},{"key":"10.1016\/j.yebeh.2020.107580_b0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2009.08.046","article-title":"Cognitive impairment in major depression","volume":"626","author":"Marazziti","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2020.107580_b0060","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/ane.12372","article-title":"Cognitive effects of lacosamide as adjunctive therapy in refractory epilepsy","volume":"131","author":"Ijff","year":"2015","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1016\/j.yebeh.2020.107580_b0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ebcr.2018.02.004","article-title":"Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine","volume":"10","author":"Liguori","year":"2018","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.yebeh.2020.107580_b0070","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.yebeh.2012.11.052","article-title":"The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting","volume":"26","author":"Helmstaedter","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107580_b0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.seizure.2018.04.015","article-title":"Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting","volume":"58","author":"Meschede","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107580_b0080","doi-asserted-by":"crossref","unstructured":"Zaccara G, Perucca P, Loiacono G, Giovannelli F, Verrotti A. The adverse event profile of lacosamide: a systematic review and meta\u2010analysis of randomized controlled trials. Epilepsia 2013;54:66\u201374.","DOI":"10.1111\/j.1528-1167.2012.03589.x"},{"key":"10.1016\/j.yebeh.2020.107580_b0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","article-title":"Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials","volume":"52","author":"Biton","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107580_b0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yebeh.2016.04.049","article-title":"The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy","volume":"61","author":"Lancman","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107580_b0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40801-016-0077-2","article-title":"Systematic adverse drug reaction monitoring of patients under newer antiepileptic drugs using routine clinical data of inpatients","volume":"3","author":"Hilgers","year":"2016","journal-title":"Drugs - Real World Outcomes"},{"key":"10.1016\/j.yebeh.2020.107580_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2017.04.010","article-title":"Tolerability of lacosamide or zonisamide in elderly patients with seizures","volume":"49","author":"Sarkis","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107580_b0105","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s13760-019-01098-3","article-title":"Lacosamide in patients with intellectual disability and refractory epilepsy","volume":"119","author":"Kleist","year":"2019","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.yebeh.2020.107580_b0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11940-008-0026-9","article-title":"Treatment of epilepsy in the elderly","volume":"10","author":"Leppik","year":"2008","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.yebeh.2020.107580_b0115","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.eplepsyres.2013.05.002","article-title":"Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation","volume":"106","author":"Novy","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.107580_b0120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0404.2004.00324.x","article-title":"The psychiatric comorbidity of epilepsy","volume":"110","author":"Gaitatzis","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.107580_b0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0920-1211(02)00008-6","article-title":"Psychiatric complications in patients with epilepsy: a review","volume":"49","author":"Marsh","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.107580_b0130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107580_b0135","doi-asserted-by":"crossref","first-page":"s65","DOI":"10.1111\/j.1528-1157.1999.tb00887.x","article-title":"Psychiatric syndromes related to antiepileptic drugs","volume":"40","author":"Schmitz","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107580_b0140","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.yebeh.2017.05.001","article-title":"Effects of adjunctive lacosamide on mood and quality of life in patients with epilepsy","volume":"73","author":"Nakhutina","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107580_b0145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.yebeh.2017.10.032","article-title":"Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: a prospective multicenter study","volume":"79","author":"Rocamora","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107580_b0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yebeh.2017.04.003","article-title":"Psychiatric side effects and antiepileptic drugs: observations from prospective audits","volume":"71","author":"Stephen","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107580_b0155","doi-asserted-by":"crossref","first-page":"106220","DOI":"10.1016\/j.eplepsyres.2019.106220","article-title":"Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: post hoc analysis of a prospective, randomized, double-blind trial","volume":"159","author":"Schmitz","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.107580_b0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.yebeh.2016.02.041","article-title":"A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures","volume":"58","author":"Steinhoff","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107580_b0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yebeh.2017.05.031","article-title":"Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: a prospective explorative study with a historical control group","volume":"73","author":"Maschio","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107580_b0170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eplepsyres.2014.12.007","article-title":"The effects of lacosamide on depression and anxiety in patients with epilepsy","volume":"110","author":"Moseley","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.107580_b0175","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/14656566.2017.1309025","article-title":"How can we overcome neuropsychological adverse effects of antiepileptic drugs?","volume":"18","author":"Witt","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2020.107580_b0180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00023210-200923020-00003","article-title":"Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors","volume":"23","author":"Mula","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2020.107580_b0185","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.yebeh.2012.09.018","article-title":"Antiepileptic drug effects on mood and behavior: molecular targets","volume":"26","author":"Perucca","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107580_b0190","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s12035-014-8775-9","article-title":"Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide","volume":"51","author":"Wilson","year":"2015","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.yebeh.2020.107580_b0195","doi-asserted-by":"crossref","unstructured":"Kudlacek J, Chvojka J, Posusta A, Kovacova L, Hong SB, Weiss S, et al. Lacosamide and levetiracetam have no effect on sharp-wave ripple rate. Front Neurol 2017;8:687.","DOI":"10.3389\/fneur.2017.00687"},{"key":"10.1016\/j.yebeh.2020.107580_b0200","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3233\/JAD-2011-110617","article-title":"CRMP2 hyperphosphorylation is characteristic of Alzheimer's disease and not a feature common to other neurodegenerative diseases","volume":"27","author":"Williamson","year":"2011","journal-title":"JAD"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020307605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020307605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:33:06Z","timestamp":1761503586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505020307605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":40,"alternative-id":["S1525505020307605"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107580","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107580"}}